Skip To Main Content
Yu HA on Muck Rack

Yu HA

As seen in: Wiley Online Library, Oxford University Press (OUP), Elsevier, Asian Nursing Research
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Yu HA’s profile

Articles by Yu HA

Structural Change of Policy Networks and Legislative Breakthrough: A 20-Year Discourse Network Analysis of Nursing Legislation in South Korea

|
By Young Gyu Kwon, Yu HA, Daun Jeong, Mi Kyung Kim, Chan Kim
| Asian Nursing Research Verified
1Center for Chung-Ang Medical Education Resource Allocation (CAMERA), College of Medicine, Chung-Ang University, Dongjak-gu, Seoul, Republic of Korea 2Department of AI in Medicine, Graduate School, Chung-Ang University, Dongjak-gu, Seoul, Republic of Korea 3Center for Medical AI Research and Education (CAU-MEDAI), Chung-Ang University, Dongjak-gu, Seoul, Republic of Korea 4Department of Emergency Medicine, College of Medicine, Chung-Ang University, Dongjak-gu, Seoul, Republic of Korea...
Open in Who Shared Issue with article?

CEO cultural heritage and R&D expenditures

|
By Yu HA, Jangkoo Kang, Kyung Yoon Kwon
| Wiley Online Library Verified
CONFLICT OF INTEREST STATEMENT The authors declare no conflicts of interest. Supporting Information Filename Description ijfe2970-sup-0001-Tables.docxWord 2007 document , 76.8 KB Table A1. Sample distribution. Table A2. Sample selection. Table A3. Correlation matrix. Table A4. IV analysis. Table A5. CEO power distance and R&D investment efficiency after controlling for CEO overconfidence. Table A6. CEO power distance and R&D investment efficiency. Table A7. CEO culture, career, and R&D increases. Table A8.
Open in Who Shared Issue with article?

HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC

|
By Yu HA, Yang JC, Fan PD, Sternberg DW
| ncbi.nlm.nih.gov
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Open in Who Shared View Duplicates (634) Issue with article?

Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers†

|
By Yu HA, Sima CC, Feldman DD
| Oxford University Press (OUP)
Patients with EGFR-mutant lung cancers treated with EGFR tyrosine kinase inhibitors (TKIs) develop clinical resistance, most commonly with acquisition of EGFR T790M. Evolutionary modeling suggests that a schedule of twice weekly pulse and daily low-dose erlotinib may delay emergence of EGFR T790M. Pulse dose erlotinib has superior central nervous system (CNS) penetration and may result in superior CNS disease control.
Open in Who Shared Issue with article?
Show More